VIR News and Press, Vir Biotechnology Inc. From 07/21/22

A newly published study indicates that Evusheld, a monoclonal antibody therapy developed by AstraZeneca ( NASDAQ: AZN ) which is available in the U.S. for pre-exposure prophylaxis of COVID-19 might be less effective against new sub lineages of Omicron. The study was designed...

Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...

Vir Biotechnology ( NASDAQ: VIR ) announced that Herbert “Skip” Virgin, M.D., Ph.D., executiveVP, research and chief scientific officer, will step down effective August 31, 2022. He will pursue a new position as chief medical officer and head of the Altos Ins...

SAN FRANCISCO, July 14, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief scientific officer, will step down effective August 31, 2022 to pursue a ne...

In my view, the two cheapest areas of the stock market are crypto stocks and biotechs fighting COVID-19. Mr. Market says these sectors are dead, so these stocks are priced to sell. I hope I'm wrong, but I think COVID will strike again this winter -- just like it did in the winter of 202...

According to unofficial sources, Sequoia China has raised about $9 billion to make investments in China’s healthcare and tech companies, above its $8 billion target. ClinChoice, a US-China-EU clinical CMO, closed a $150 million Series E round financing from China investors. ...

The National Institutes of Health (NIH) aims to enroll nearly 40,000 people this year as part of one of the largest research efforts to understand long COVID, a condition affecting an estimated one in five COVID-19 survivors aged 18 – 64 in the U.S. The $1.15B government fund...

Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug f...

Vir Biotechnology (NASDAQ:VIR) said preliminary day showed that a six-dose regimen of VIR-2218 provided greater and more durable reductions in hepatitis B surface antigen (HBsAg) than a two-dose regimen, in a phase 2 trial. The company presented data from its hepatitis B virus (HBV) trial pro...

– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the ...